6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies
Key Takeaways
- Cardiogenic shock is defined hemodynamically by a low Cardiac Index (<2.2 L/min/m²), elevated PAOP (>15-18 mmHg), elevated SVR (>1500 dyn·s·cm⁻⁵), and reduced Cardiac Power Output (<0.6 W).
- The SCAI Shock Classification stratifies patient acuity from Stage A (At risk) to Stage E (Extremis), guiding timely escalation of vasopressors, inotropes, and percutaneous mechanical circulatory support.
- Acute myocardial infarction causing >40% LV necrosis is the leading etiology, but acute mechanical complications (mitral regurgitation, VSD, free wall rupture) must be evaluated rapidly via echocardiography.
- Norepinephrine is the preferred initial vasopressor for restoring MAP, while Dobutamine or Milrinone provide inotropic support; early mechanical circulatory support (Impella, VA-ECMO) should be initiated before multi-organ failure ensues.
- Hemodynamic management of the 'Cold and Wet' patient requires balancing afterload reduction, inotropic contractility support, and cautious decongestion with loop diuretics.
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies
Cardiogenic shock (CS) is a state of severe end-organ hypoperfusion resulting from primary cardiac dysfunction. Despite advances in percutaneous coronary intervention (PCI) and mechanical circulatory support (MCS), cardiogenic shock carries a 30-day mortality rate approaching 40% to 50%. For the AACN CMC certification exam, nurses must master hemodynamic calculations, SCAI shock staging, vasoactive titration strategies, mechanical complication identification, and MCS escalation pathways.
Pathophysiologic Spiral of Cardiogenic Shock
The fundamental defect in cardiogenic shock is severe impairment of myocardial contractility, resulting in a reduced stroke volume (SV) and cardiac output (CO). This triggers a deleterious neurohormonal compensatory cascade:
- Myocardial Insult: Loss of functional myocardium (most commonly >40% of left ventricular mass during acute myocardial infarction) leads to elevated left ventricular end-diastolic pressure (LVEDP) and decreased CO.
- Compensatory Neurohormonal Activation: Hypoperfusion triggers sympathetic nervous system (SNS) activation and renin-angiotensin-aldosterone system (RAAS) stimulation.
- Systemic Vasoconstriction: Endogenous catecholamines, angiotensin II, and vasopressin markedly increase Systemic Vascular Resistance (SVR) to preserve Mean Arterial Pressure (MAP).
- Increased Myocardial Oxygen Demand: Elevated afterload (SVR) and wall stress (LVEDP) increase myocardial oxygen consumption (MVO₂), further worsening myocardial ischemia in non-infarcted and stunned cardiac tissue.
- Pulmonary & Systemic Congestion: Elevated LVEDP retrogrades into the left atrium and pulmonary venous circulation, resulting in pulmonary capillary hydrostatic pressure exceeding plasma oncotic pressure (>18-20 mmHg), causing acute hydrostatic pulmonary edema and hypoxemia.
Invasive Hemodynamic Profiling & Diagnostic Metrics
Definitive diagnosis and continuous monitoring of cardiogenic shock rely on invasive hemodynamic monitoring via Pulmonary Artery Catheterization (PAC) and arterial lines.
| Hemodynamic Parameter | Standard Reference Range | Cardiogenic Shock Profile | Clinical Significance & Calculation |
|---|---|---|---|
| Cardiac Output (CO) | 4.0 – 8.0 L/min | < 4.0 L/min | CO = HR × SV; total volume pumped per minute |
| Cardiac Index (CI) | 2.5 – 4.0 L/min/m² | < 2.2 L/min/m² (or <1.8 without support) | CI = CO / BSA; indexed to body surface area |
| Pulmonary Artery Occlusion Pressure (PAOP) | 8 – 12 mmHg | > 15 – 18 mmHg | Reflects LVEDP and left heart filling pressure |
| Systemic Vascular Resistance (SVR) | 800 – 1200 dynes·sec/cm⁵ | > 1500 dynes·sec/cm⁵ | SVR = [(MAP - CVP) / CO] × 80; reflects LV afterload |
| Central Venous Pressure (CVP) | 2 – 6 mmHg | > 10 – 15 mmHg | Reflects right atrial pressure and right heart volume |
| Cardiac Power Output (CPO) | 0.7 – 1.1 Watts | < 0.6 Watts | CPO = (MAP × CO) / 451; strongest hemodynamic mortality predictor |
| Pulmonary Artery Pulsatility Index (PAPi) | > 2.0 | < 0.9 – 1.0 | PAPi = (PASP - PADP) / CVP; sensitive indicator of RV failure |
| Mixed Venous O₂ Saturation (SvO₂) | 65% – 75% | < 60% | Decreased due to high tissue oxygen extraction ratio |
Cardiac Power Output (CPO) & PAPi Calculations
- Cardiac Power Output (CPO): CPO is calculated as MAP × CO/451. A resting CPO below 0.6 Watts despite initial pharmacological intervention indicates severe catastrophic pump failure and is the primary hemodynamic threshold for escalating to percutaneous mechanical circulatory support.
- Pulmonary Artery Pulsatility Index (PAPi): Calculated as PASP - PADP/CVP. A PAPi value below 0.9 in the setting of acute inferior MI or left ventricular assist device (LVAD) evaluation strongly indicates acute Right Ventricular (RV) failure.
SCAI Shock Classification & Acuity Staging
The Society for Cardiovascular Angiography and Interventions (SCAI) established a standardized 5-stage shock classification system to guide clinical evaluation and escalation of care.
| SCAI Stage | Name | Hemodynamic & Clinical Features | Lactate & Perfusion Markers | Recommended Management |
|---|---|---|---|---|
| Stage A | At Risk | Normal hemodynamics (CI >2.5, PAOP normal), no clinical hypoperfusion; large acute MI, acute myocarditis, or acute HF exacerbation. | Normal lactate (<2.0 mmol/L), normal renal/liver function. | Close telemetry/ICU monitoring, guideline-directed medical therapy. |
| Stage B | Beginning | Sinus tachycardia, narrow pulse pressure, mild hypotension (SBP <90 mmHg or MAP <65 mmHg) without clinical hypoperfusion. | Normal lactate (<2.0 mmol/L), preserved urine output (>0.5 mL/kg/h). | Volume trial if PAOP low, modest vasopressor initiation if hypotensive. |
| Stage C | Classic | Hypoperfusion requiring vasoactive infusions or mechanical support to maintain systemic perfusion; CI <2.2, PAOP >15. | Elevated lactate (>2.0–4.0 mmol/L), oliguria, cool extremities, altered mental status. | Invasive PAC monitoring, combination vasopressor/inotrope infusion, early MCS evaluation. |
| Stage D | Deteriorating | Failure of initial interventions (vasopressors/inotropes) to restore stability after 30–60 minutes; escalating drug requirements. | Rising lactate (>4.0 mmol/L), worsening metabolic acidosis, progressive renal/hepatic injury. | Rapid escalation to percutaneous MCS (Impella, VA-ECMO), multidisciplinary shock team activation. |
| Stage E | Extremis | Refractory cardiac arrest, ongoing CPR, severe combined metabolic/lactic acidosis, circulatory collapse. | Lactate >8.0–10.0 mmol/L, pH <7.15, multi-organ breakdown. | E-CPR, emergent VA-ECMO cannulation, salvage advanced mechanical support. |
Clinical Etiologies & Acute Mechanical Complications of AMI
While acute myocardial infarction (AMI) accounts for ~80% of cardiogenic shock cases, critical care nurses must differentiate primary LV muscular failure from acute mechanical complications of AMI, which present with sudden hemodynamic collapse typically 2 to 7 days post-infarction.
Acute Mechanical Complications of AMI
- Acute Papillary Muscle Rupture (Acute Mitral Regurgitation):
- Mechanism: Necrosis of the posteromedial papillary muscle (single blood supply from the Posterior Descending Artery / RCA). Causes catastrophic holosystolic regurgitation into a non-compliant left atrium.
- Clinical Signs: Sudden pulmonary edema, new harsh holosystolic murmur at apex radiating to axilla, giant v-waves on PAOP waveform tracing.
- Management: Immediate IV Nitroprusside (if SBP permits) or IABP for afterload reduction, urgent surgical valve repair/replacement.
- Ventricular Septal Defect (VSD):
- Mechanism: Transmural necrosis of the anterior or inferior septum creating a left-to-right shunt.
- Clinical Signs: Harsh, loud holosystolic murmur at left lower sternal border with a palpable thrill; oxygen saturation step-up ≥ 10% between the Right Atrium (RA) and Right Ventricle (RV) / Pulmonary Artery (PA).
- Management: Emergency IABP or Impella placement, urgent surgical or percutaneous closure.
- Free Wall Rupture:
- Mechanism: Full-thickness myocardial tear leading to rapid hemopericardium and cardiac tamponade.
- Clinical Signs: Sudden electromechanical dissociation (PEA), Beck's triad (hypotension, JVD, muffled heart sounds), pulsus paradoxus.
- Management: Immediate bedside pericardiocentesis and emergency open thoracotomy.
Pharmacological Vasoactive Management
Vasopressors and inotropes are essential for stabilization but must be titrated cautiously to avoid excessive myocardial oxygen consumption (MVO₂) and arrhythmogenesis.
| Agent | Primary Receptor Activity | Hemodynamic Effects | Dosing Guidelines | Clinical Indications & Considerations |
|---|---|---|---|---|
| Norepinephrine | α₁ > beta₁ | ↑↑ MAP, ↑ SVR, modest ↑ CO | Initial: 0.02 – 0.05 mcg/kg/min; Titrate to MAP ≥ 65 mmHg | First-line vasopressor in CS; less arrhythmogenic and less tachycardia than dopamine. |
| Dobutamine | beta₁ > beta₂ > α₁ | ↑↑ CO/CI, ↓ PAOP, ↓ SVR (inodilator) | Initial: 2.5 – 5.0 mcg/kg/min; Range: 2.5 – 20 mcg/kg/min | First-line inotrope for low CI with adequate MAP; causes tachycardia and ventricular ectopy. |
| Milrinone | PDE-3 inhibitor | ↑↑ CO/CI, ↓↓ SVR, ↓↓ PVR (inodilator) | Initial: 0.125 – 0.25 mcg/kg/min (no bolus in shock) | Ideal for pulmonary hypertension or concomitant RV failure; renal clearance (dose reduce in AKI). |
| Epinephrine | beta₁ = beta₂ > α₁ (low dose)<br>α₁ > beta₁ (high dose) | ↑↑ MAP, ↑↑ CO, ↑ SVR | Initial: 0.01 – 0.05 mcg/kg/min; Titrate up to 0.5 mcg/kg/min | Second-line agent for refractory shock; causes hyperlactatemic metabolic acidosis and marked tachycardia. |
| Vasopressin | V₁ₐ receptors | ↑↑ SVR, ↑ MAP, no change in HR/CO | Fixed dose: 0.03 units/min (do not titrate) | Adjunctive non-adrenergic vasopressor for vasoplegic shock; does not increase pulmonary vascular resistance. |
Mechanical Circulatory Support (MCS) Escalation Timing
When vasopressors and inotropes fail to achieve a CI > 2.2 L/min/m² or CPO > 0.6 W, percutaneous MCS must be deployed rapidly.
CARDIOGENIC SHOCK PROFILE
(CI <2.2, PAOP >15-18, CPO <0.6W, MAP <65)
│
▼
┌─────────────────────────────────────┐
│ Initial Pharmacotherapy & PAC Setup │
│ Norepinephrine + Dobutamine/Milrinone│
└──────────────────┬──────────────────┘
│
Is Patient Stabilized?
(CI >2.2, Lactate Down)
│ │
YES ───────┘ └─────── NO (SCAI C/D/E)
│ │
▼ ▼
Continue Titration Select Percutaneous MCS
De-escalate Drips │
├──────────────────────────┐
▼ ▼
Isolated LV Failure Severe Biventricular /
(Impella CP / 5.5) Pulmonary Collapse
│ (VA-ECMO ± Impella)
▼ │
Direct LV Unloading ▼
↓LVEDP, ↓MVO2, ↑CO Full Biventricular &
Gas Exchange Support
Comparison of Mechanical Support Devices
- Intra-Aortic Balloon Pump (IABP): Positioned in descending thoracic aorta distal to left subclavian artery. Diastolic inflation increases coronary artery perfusion pressure; systolic deflation reduces LV afterload and stroke work. Provides modest CO increase (~0.5 L/min). Contraindicated in Aortic Regurgitation and Aortic Dissection.
- Impella (2.5, CP, 5.0, 5.5): Catheter-based microaxial flow pump positioned across aortic valve. Draws blood directly from LV and expels into ascending aorta. Delivers 2.5 to 5.5 L/min continuous flow, actively unloading the LV, reducing wall stress and PAOP, and dramatically decreasing MVO₂.
- Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO): Cannulated via femoral vein (drainage) and femoral artery (reinfusion). Provides 5 to 7 L/min full biventricular and pulmonary oxygenation support. Key Drawback: Increased retrograde aortic blood flow increases LV afterload and LVEDP, potentially worsening pulmonary edema. Co-administration of an Impella with VA-ECMO (ECPELLA) is increasingly utilized to achieve LV venting.
A patient with acute anterior STEMI is admitted to the CICU with a pulmonary artery catheter in place. Parameters reveal: MAP 58 mmHg, Heart Rate 112 bpm, Cardiac Output 3.1 L/min, Body Surface Area 2.0 m² (Cardiac Index 1.55 L/min/m²), and PAOP 22 mmHg. What is the patient's calculated Cardiac Power Output (CPO), and what clinical decision does this threshold indicate?
On post-infarction day 4 following an inferior STEMI, a patient experiences sudden hemodynamic collapse. Examination reveals a new, loud holosystolic murmur at the apex radiating to the axilla, pulmonary edema, and a PAOP waveform demonstrating giant v-waves (38 mmHg). Which acute mechanical complication has occurred, and what is the immediate hemodynamic intervention?
A patient in cardiogenic shock is cannulated for femoral Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO). Serial echocardiography reveals a non-opening aortic valve, worsening left ventricular distension, and severe pulmonary edema. What is the pathophysiologic mechanism of this complication, and what is the definitive solution?